Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R C Dage

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
British Journal of Pharmacology|January 1, 1979
A centrally mediated prolonged hypotension produced by oxotremorine or pilocarpineR C Dage
Molecular Pharmacology|April 1, 1992
Functional interactions between two Ca2+ channel activators, (S)-Bay K 8644 and FPL 64176, in smooth muscleD Rampe, R C Dage
Biochemical Pharmacology|September 1, 1988
Tissue distribution and selective inhibition of subtypes of high affinity cAMP phosphodiesteraseT Kariya, R C Dage
Neurochemistry International|May 28, 2010
Effects of inhibitors of protein kinase C and phosphodiesterase on the contractile effects of endothelin in dog femoral arteryH C Cheng, R C Dage
British Journal of Pharmacology|October 1, 1980
Direct vasodilatation by labetalol in anaesthetized dogsR C Dage, C P Hsieh
Journal of Cardiovascular Pharmacology|September 1, 1990
Delay of occurrence of reperfusion-induced ventricular fibrillation in the isolated rat heart with superoxide dismutaseJ E Koerner, R C Dage
Journal of Cardiovascular Pharmacology|September 1, 1990
Antiarrhythmic and electrophysiologic effects of MDL 11,939, a novel class III antiarrhythmic agent in anesthetized dogsJ E Koerner, R C Dage
Cardiology|January 1, 1990
Pharmacology and pharmacokinetics of enoximoneR C Dage, R A Okerholm
Journal of Cardiovascular Pharmacology|January 1, 1984
Studies on the mechanism of the cardiotonic activity of MDL 19205: effects on several biochemical systemsT Kariya, L J Wille, R C Dage
Journal of Cardiovascular Pharmacology|December 1, 1990
Effects of MDL 11,939 on action potential and contractile force in cardiac tissues: a comparison with bretylium, clofilium, and sotalolT Li, A A Carr, R C Dage
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
British Journal of Pharmacology|January 1, 1979
A centrally mediated prolonged hypotension produced by oxotremorine or pilocarpineR C Dage
Molecular Pharmacology|April 1, 1992
Functional interactions between two Ca2+ channel activators, (S)-Bay K 8644 and FPL 64176, in smooth muscleD Rampe, R C Dage
Biochemical Pharmacology|September 1, 1988
Tissue distribution and selective inhibition of subtypes of high affinity cAMP phosphodiesteraseT Kariya, R C Dage
Neurochemistry International|May 28, 2010
Effects of inhibitors of protein kinase C and phosphodiesterase on the contractile effects of endothelin in dog femoral arteryH C Cheng, R C Dage
British Journal of Pharmacology|October 1, 1980
Direct vasodilatation by labetalol in anaesthetized dogsR C Dage, C P Hsieh
Journal of Cardiovascular Pharmacology|September 1, 1990
Delay of occurrence of reperfusion-induced ventricular fibrillation in the isolated rat heart with superoxide dismutaseJ E Koerner, R C Dage
Journal of Cardiovascular Pharmacology|September 1, 1990
Antiarrhythmic and electrophysiologic effects of MDL 11,939, a novel class III antiarrhythmic agent in anesthetized dogsJ E Koerner, R C Dage
Cardiology|January 1, 1990
Pharmacology and pharmacokinetics of enoximoneR C Dage, R A Okerholm
Journal of Cardiovascular Pharmacology|January 1, 1984
Studies on the mechanism of the cardiotonic activity of MDL 19205: effects on several biochemical systemsT Kariya, L J Wille, R C Dage
Journal of Cardiovascular Pharmacology|December 1, 1990
Effects of MDL 11,939 on action potential and contractile force in cardiac tissues: a comparison with bretylium, clofilium, and sotalolT Li, A A Carr, R C Dage
Pageof 5